Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 82-86, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Etienne, M. C.
Right arrow Articles by Milano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etienne, M. C.
Right arrow Articles by Milano, G.

Clinical Chemistry, Vol 39, 82-86, Copyright © 1993 by American Association for Clinical Chemistry

HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma

MC Etienne, N Speziale and G Milano
Centre Antoine Lacassagne, Laboratoire d'oncopharmacologie, Nice, France.

We present a rapid, sensitive, and automated HPLC method with direct resolution of l-folinic acid (l-FA), d-folinic acid (d-FA), and 5- methyltetrahydrofolate (5MTHF) from plasma samples. Plasma (500 microL) is first extracted on solid phase (RP-18 cartridge). The dI-FA peak is collected on-line from a reversed-phase column (RP-8, 119 x 2 mm, 4 microns: HPLC 1) and then automatically loaded onto a chiral stationary phase (human serum albumin, 150 x 4.6 mm, 7 microns: HPLC 2). The same mobile phase flows in both systems (0.2 mol/L Na2HPO4:1-propanol, 98:2, pH 6.2). HPLC 1 allows quantification of 5MTHF by absorption at 313 nm; HPLC 2, the quantification of l-FA and d-FA by electrochemical detection in the oxidation mode (total run time 18 min). Recoveries are > 80%. CVs for intra- and interassay reproducibilities are < 5% and 15%, respectively. Linearity of the response (0.1-1 mumol/L and 1-50 mumol/L, r = 0.99, P < 0.01) is satisfactory. The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA. This assay is substantially improved over existing methods regarding feasibility and is being used in pharmacokinetic investigations in cancer patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 JCOHome page
K. Shirao, P.M. Hoff, A. Ohtsu, P.J. Loehrer, I. Hyodo, S. Wadler, R.G. Wadleigh, P.J. O'Dwyer, K. Muro, Y. Yamada, et al.
Comparison of the Efficacy, Toxicity, and Pharmacokinetics of a Uracil/Tegafur (UFT) Plus Oral Leucovorin (LV) Regimen Between Japanese and American Patients With Advanced Colorectal Cancer: Joint United States and Japan Study of UFT/LV
J. Clin. Oncol., September 1, 2004; 22(17): 3466 - 3474.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Damle, F. Ravandi, S. Kaul, D. Sonnichsen, I. Ferreira, D. Brooks, D. Stewart, D. Alberts, and R. Pazdur
Effect of Food on the Oral Bioavailability of UFT and Leucovorin in Cancer Patients
Clin. Cancer Res., March 1, 2001; 7(3): 517 - 523.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.